J&J CEO Duato sells $12.5m in company stock By Investing.com

Joaquin Duato, CEO and Chairman of the Board at (JNJ), disposed of company stock totaling approximately $12.51 million on August 5, 2026, according to a recent regulatory filing.

The transactions involved two separate sales of common stock. Mr. Duato sold 41,957 shares at a weighted average price of $258.056 per share. These shares were sold in multiple trades with prices ranging from $257.53 to $258.505. Additionally, he sold 6,523 shares at a weighted average price of $258.739 per share, with individual trade prices ranging from $258.535 to $259.10. The combined sales represent a total value of $12,515,010, with prices for all shares sold ranging between $257.53 and $259.10.The sale comes as JNJ stock has delivered a strong 53% return over the past year, currently trading at $259.24. According to InvestingPro analysis, the stock remains undervalued relative to its Fair Value, with one of the platform’s key ProTips highlighting that JNJ has raised its dividend for 55 consecutive years. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for JNJ and 1,400+ other US equities.

Following these transactions, Mr. Duato directly holds 275,967 shares of Johnson & Johnson common stock. He also indirectly beneficially owns 1,018 shares through a 401k plan, which includes shares accrued from dividend reinvestment as of July 31, 2026, and 30,852 shares held by his spouse.

In other recent news, Johnson & Johnson reported second-quarter results that exceeded expectations. The company’s sales grew by 5.7% on an organic basis, with pharmaceutical revenue increasing by 6.9% and medical technology revenue rising by 3.7%, surpassing estimates by 1.1%. Following this strong performance, Freedom Capital upgraded Johnson & Johnson’s stock rating to Buy from Hold and increased its price target to $280 from $230. The firm highlighted that TREMFYA revenue was approximately $400 million above its projections, with CAPLYTA and SPRAVATO also significantly outperforming expectations.

Bernstein SocGen Group also raised its price target on Johnson & Johnson shares to $261 from $251, maintaining a Market Perform rating after the company’s earnings beat. Additionally, Guggenheim increased its price target to $287 from $270, maintaining a Buy rating, following a site visit with senior management discussing new products. Raymond James raised its price target to $280 from $265, citing the recent FDA approval and limited launch of the Ottava robotic surgery platform. These developments reflect a positive outlook from analysts on Johnson & Johnson’s recent performance and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.